Clovis Oncology reported $22.93M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
Acorda Therapeutics ACOR:US $ 22.25M 5.68M
Agenus AGEN:US $ 18.9M 6.5M
Agios Pharmaceuticals AGIO:US $ 5.15M 4.65M
Anika Therapeutics ANIK:US $ 24.86M 3.06M
AstraZeneca AZN:LN 8.87B 244M
Astrazeneca AZN:US 8.87B 244M
Clovis Oncology CLVS:US $ 22.93M 1.91M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Esperion Therapeutics ESPR:US $ 9.66M 2.05M
GlaxoSmithKline GSK:LN 4.79B 1.34B
Halozyme Therapeutics HALO:US $ 118.42M 17.07M
Insmed INSM:US $ 48.83M 7.91M
Merk MRK:US $ 10895M 328M
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Novartis NOVN:VX 9.34B 277M
Pfizer PFE:US $ 19071M 3420M
Puma Biotechnology PBYI:US $ 44.6M 9.71M
Seattle Genetics SGEN:US $ 391.4M 52.57M
Ultragenyx Pharmaceutical RARE:US $ 81.07M 7.24M
Veracyte VCYT:US $ 47.83M 3.76M
YTE INCY:US $ 866.16M 170.14M